Panacea Biotec Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Panacea Biotec Ltd.
India clears Russian vaccine for restricted use, adding a third vaccine to its arsenal in the fight against COVID-19. One local expert highlights the vaccine’s “clever design” amid hopes that it will hold good against variants as well.
AstraZeneca has sent a legal notice to Indian partner Serum Institute for non-delivery of COVID-19 vaccines. Will this and the entry of a new challenger, Sputnik V, in the Indian market affect Serum’s fortunes? Will the EMA and MHRA announcement on clotting incidents related to the AZ vaccine shrink demand for the partnered vaccine?
Russian sovereign wealth fund and Sputnik V vaccine producer RDIF has teamed up with the country’s biggest bank to fund ‘home-grown’ tech and science-intensive start-ups.
Global research consortium to investigate the use of immunoglobulin as a COVID-19 therapy ends following disappointing results from a Phase III trial. Meanwhile, Russian vaccine producer RDIF is snapping up more production capacity in India, where interferon has also progressed as a possible treatment.
- Contract Research, Toxicology Testing-CRO
- Drug Delivery
- OTC, Consumer